Quisinostat CAS:875320-29-9

CAS NO: 875320-29-9
Quisinostat CAS:875320-29-9
Description Review
Description

JNJ-26481585, also known as JNJ26481585 or Quisinostat, is a small molecule inhibitor of histone deacetylase (HDAC), which is an enzyme involved in the regulation of gene expression through chromatin modification. It was first discovered in 2008 and has since been studied for its potential as a treatment for various types of cancer.

Chemical name:

The chemical name for JNJ-26481585 is N-hydroxy-2-(2-methyl-1H-indol-4-yl)thiazole-4-carboxamide.

Molecular formula:

The molecular formula of JNJ-26481585 is C14H12N4O2S.

Formula weight:

The formula weight of JNJ-26481585 is 308.34 g/mol.

CAS No:

The CAS number of JNJ-26481585 is 875320-29-9.

Top ten keywords from Google and Synonyms:

  1. JNJ-26481585 clinical trials
  2. JNJ-26481585 mechanism of action
  3. JNJ-26481585 cancer treatment
  4. JNJ-26481585 pharmacokinetics
  5. JNJ-26481585 toxicity
  6. JNJ-26481585 side effects
  7. JNJ-26481585 synthesis
  8. Histone deacetylase inhibitor JNJ-26481585
  9. HDAC inhibitor Quisinostat
  10. MGCD0103

Synonyms:

  1. 875320-29-9
  2. HDAC inhibitor Quisinostat

Health benefits of this product:

JNJ-26481585 has been primarily developed for the treatment of cancer. As an HDAC inhibitor, it is thought to regulate gene expression by promoting acetylation of histones, leading to changes in chromatin structure and gene transcription.

Potential effects:

Some potential effects of JNJ-26481585 include:

  1. Inhibition of tumor growth
  2. Reduction of cancer cell proliferation
  3. Induction of apoptosis (programmed cell death)
  4. Sensitization of cancer cells to other therapies

Product mechanism:

JNJ-26481585 works by inhibiting HDAC, which is an enzyme involved in the regulation of gene expression through chromatin modification. By inhibiting HDAC, JNJ-26481585 can promote acetylation of histones, leading to changes in chromatin structure and gene transcription.

Safety:

JNJ-26481585 has been tested in preclinical and clinical studies for its safety profile. The drug has been found to have acceptable toxicity and has not shown any significant adverse effects on normal tissues or organs. However, as with any medication, there are some risks associated with its use. Patients should inform their healthcare provider of any pre-existing medical conditions or medications they are taking before starting treatment with JNJ-26481585.

Side effects:

JNJ-26481585 can cause several side effects in some patients. These can include:

  1. Fatigue
  2. Nausea
  3. Vomiting
  4. Diarrhea
  5. Anorexia
  6. Constipation
  7. Headache
  8. Dizziness
  9. Hypotension

Dosing information:

The optimal dosing regimen of JNJ-26481585 has not yet been established and further research is needed to determine the most effective dose. In preclinical studies, doses ranged from 10 to 100 mg/kg. In clinical trials, doses ranged from 20 to 50 mg once daily. The drug is typically administered orally.

Conclusion:

JNJ-26481585 is a small molecule inhibitor of HDAC that has shown potential as a treatment for various types of cancer. By inhibiting HDAC, JNJ-26481585 may regulate gene expression by promoting acetylation of histones, leading to changes in chromatin structure and gene transcription. The drug has undergone several preclinical and clinical trials and has been found to have an acceptable safety profile. However, as with any medication, there are some risks associated with its use. Further research is needed to determine the optimal dosing regimen and efficacy of JNJ-26481585 in treating various types of cancer.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code